

# The Expression and Localization of Kappa Myeloma Antigen on Malignant and Normal B cells

Andrew Tasman Hutchinson

A thesis submitted in fulfilment of the  
requirements for the degree of  
Doctor of Philosophy

University of Technology, Sydney  
NSW, Australia

August 2009

## **Certificate of Authorship/Originality**

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the written preparation of the thesis, and all experimental work associated with it, has been carried out solely by me, unless otherwise indicated. Finally, I certify that all information sources and literature used are acknowledged in the text.

Production Note:  
Signature removed prior to publication.

**Andrew Tasman Hutchinson**  
**August 2009**

## **Acknowledgements**

I would first like to thank my supervisors and good friends, Professor Bob Raison and Darren Jones. Bob was instrumental in getting my PhD off the ground with Immune System Therapeutics Ltd and I am grateful for the time and patience he dedicated to my project. He never once held me back from chasing even the most outrageous hypotheses and provided both support, and more importantly, a critical examination during the creative process. Bob, I wish you all the best for your retirement and congratulate you on your recent appointment as Emeritus Professor at UTS.

When I was an undergraduate ‘wash up boy’ during the early days of PacMab, Darren took me under his wing and nurtured my development as a scientist. He trained me on most aspects of working in an immunology lab, including that most invaluable technique of flow cytometry. In a wider context Darren has, and will continue to be an inspiration, having taught me the importance of science, as well as what it means to lead a balanced and ‘well-rounded’ life. Darren, it has been a great journey. I have no doubt this is only the beginning, and I am already looking forward to the next step!

To all past and present at Immune System Therapeutics Ltd / PacMab, what a ride it has been! It was with great perseverance that we got this antibody to clinical trial, and in this regard, the venture has been a tremendous success. Thank you for finding the funds to support my project throughout the years. I am grateful that I was given space to pursue basic research in a commercial environment. Hopefully something valuable will one day come out of it! In particular, I would like to thank Maria Lund and Dr Cameron Jennings.

Maria for being a dedicated and outstanding research assistant. Without the help of Maria, I would still be slaving away in the lab. She was especially helpful in working up the artificial membrane systems which became one of the main cores of my project. She did this with very little help, and for a time, the student became the master whilst she taught me these new techniques. Maria, it has been a great pleasure watching you develop into a scientist. Good luck with your upcoming honours year. I am sure you’ll continue to excel as a researcher.

Cameron for being a great work colleague and friend. He provided me with a number of materials needed to complete my studies. Cameron, and his honours student, Vanessa Bockhorni, also performed the  $\kappa$ LC HEK-293 transfections which were used as cellular models of KMA expression in this thesis.

Special thanks go to Paul Ramsland and Allen Edmundson - two generations of structural immunologists. For a long time my only goal was to try and reconcile my observations with what these structuralists thought was possible. Immunology, after all, performs its magic at the molecular level. Allen was an early supporter of the misfolded FLC theory. This eventually culminated into the aggregation hypothesis after a stimulating week of work in Paul's lab. Here we performed the dynamic light scattering measurements, as well as built the phosphocholine - FLC models. Thank you both for your interest and time in my project. It was a pleasure working alongside such accomplished scientists and individuals.

To my parents, family and friends, thank you for all your continued support and interest over the years. I am lucky to be surrounded by such a diverse and interesting bunch of people!

Finally, to my partner and best friend, Lucinda, you have been an invaluable source of encouragement, love and support. Thank you for all your patience. I am looking forward to a bright and happy future with you by my side.

## Table of Contents

<b>CERTIFICATE OF AUTHORSHIP/ORIGINALITY .....</b>	<b>i</b>
<b>ACKNOWLEDGEMENTS.....</b>	<b>ii</b>
<b>TABLE OF CONTENTS.....</b>	<b>iv</b>
<b>LIST OF FIGURES AND TABLES .....</b>	<b>viii</b>
<b>ABBREVIATIONS .....</b>	<b>x</b>
<b>ABSTRACT .....</b>	<b>1</b>
<b>CHAPTER 1: INTRODUCTION .....</b>	<b>4</b>
Section 1.1 Kappa Myeloma Antigen .....	5
Section 1.2 Immunoglobulins .....	5
1.2.1 Immunoglobulin Genes .....	5
1.2.2 Immunoglobulin Light Chain Restriction.....	9
1.2.3 Molecular Chaperones and Light Chain Synthesis .....	10
1.2.4 Free Immunoglobulin Light Chain .....	10
Section 1.3 Proposed Biological Roles of Free Immunoglobulin Light Chain .....	12
1.3.1 Antigen Recognition.....	12
1.3.2 Proteolysis .....	13
1.3.3 Type 1 Hypersensitivity .....	13
1.3.4 Anti-Angiogenesis.....	14
1.3.5 Alternative Pathway of Complement Activation.....	14
1.3.6 Inhibition of Chemotaxis.....	14
1.3.7 Anti-Apoptotic Stimulus .....	15
Section 1.4 B Cell Biology.....	15
1.4.1 B cell Development .....	15
1.4.2 B cell Activation.....	16
1.4.3 Co-Stimulatory Cell Independent Activation .....	16
1.4.4 Co-Stimulatory Cell Dependent Activation.....	17
Section 1.5 Plasma Cell Biology.....	18
1.5.1 B-1 and MZ B cell Derived Plasma Cells .....	18
1.5.2 GC Derived Plasma Cells .....	18
1.5.3 Short-Lived and Long-Lived Plasma Cells .....	19
1.5.4 Transcription Factors Involved in Plasma Cell Development .....	20
1.5.5 Phenotypic Changes Associated with Plasma Cell Differentiation .....	21
Section 1.6 Plasma Cell Related Disorders .....	22
1.6.1 Plasma Cells as Effectors of Autoimmunity.....	22
1.6.2 Multiple Myeloma.....	23
1.6.3 Waldenström's Macroglobulinaemia .....	24
1.6.4 Monoclonal Gammopathy of Undetermined Significance (MGUS).....	24
1.6.5 Diseases with Monoclonal Immunoglobulin Deposition.....	25
Section 1.7 Therapies for Plasma Cell Disorders .....	27
1.7.1 Immunomodulatory Compounds.....	27
1.7.2 Alkylation Agents.....	27
1.7.3 Glucocorticoids .....	28
1.7.4 Proteasome Inhibitors.....	28
1.7.5 Monoclonal Antibodies .....	28
Section 1.8 KMA as a Therapeutic Target .....	30
1.8.1 mKap and cKap Monoclonal Antibodies .....	30
1.8.2 mKap and cKap Mechanisms of Action.....	30
1.8.3 Expression of KMA on B cells.....	31
Section 1.9 The Plasma Membrane.....	31
1.9.1 Structure and Function of the Plasma Membrane.....	31

1.9.2 Lipid Composition.....	32
1.9.3 Lipid Rafts.....	34
Section 1.10 The Plasma Membrane.....	34
1.10.1 Integral Membrane Proteins.....	34
1.10.2 Peripheral Membrane Proteins.....	35
1.10.3 Lipid-Anchored Membrane Proteins.....	36
Section 1.11 Potential Mechanisms of F $\kappa$ LC Association as KMA.....	37
1.11.1 FLC Receptors.....	37
1.11.2 Membrane Association of FLC.....	38
Section 1.12 Aims of this Study.....	39
<b>CHAPTER 2: MATERIALS AND METHODS.....</b>	<b>40</b>
Section 2.1 General Reagents and Buffers.....	41
2.1.1 Buffers.....	41
2.1.2 Cell Lines.....	41
2.1.3 Production of mKap/cKap mAbs and F $\kappa$ LCs.....	42
2.1.4 Conjugation of Abs and Proteins.....	42
Section 2.2 Cell Biology.....	43
2.2.1 Flow Cytometry.....	43
2.2.2 Purification of Primary Cells.....	45
2.2.3 in vitro Activation of CD19+ B cells.....	46
2.2.4 $\kappa$ LC HEK-293 Transfectants.....	46
2.2.5 Heat Shock of JJN-3 Cells.....	47
2.2.6 Brefeldin A Treatment on ARH-77_100 Cells.....	47
2.2.7 Cholesterol Depletion by Methyl $\beta$ Cyclodextrin (m $\beta$ CD) on Cell Lines.....	47
2.2.8 Small Inhibitory RNA (siRNA) Knockdown of Target Genes.....	48
2.2.9 GW4869 Neutral Sphingomyelinase (N-Smase) Inhibitor Treatment on Cell Lines.....	49
2.2.10 High Salt, Low pH Washes on ARH-77_100 Cells.....	49
2.2.11 PLC, Cholesterol Esterase and O-Glycosidase Treatment on ARH-77_100 Cells.....	49
2.2.12 Confocal Fluorescence Microscopy.....	50
Section 2.3 Protein and Lipid Biology.....	51
2.3.1 Enzyme-Linked Immunosorbent Assays (ELISA).....	51
2.3.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE).....	52
2.3.3 Western Blotting.....	52
2.3.4 Preparation of Cellular Membranes.....	53
2.3.5 Immunoprecipitation of KMA with mKap.....	54
2.3.6 Sodium Carbonate Membrane Extraction.....	54
2.3.7 Triton X 114 (TX114) Phase Separation.....	55
2.3.8 Acyl-Biotin Exchange on JJN-3 Cellular Lysates.....	55
2.3.9 Analysis of the Oxidation State of F $\kappa$ LC in KMA.....	56
2.3.10 Preparation of Large Unilamellar Vesicles (LUV).....	56
2.3.11 F $\kappa$ LC Binding to LUVs: Sucrose Flotation Assay.....	57
2.3.12 Assessment of F $\kappa$ LC Binding to LUVs.....	57
2.3.13 Dynamic Light Scattering (DLS) Measurements.....	58
2.3.14 BCA Protein Assay.....	59
2.3.15 Amplex Red Total Cellular Cholesterol Assay.....	59
2.3.16 Total Cellular Sphingomyelin Assay.....	59
Section 2.4 Molecular Biology.....	60
2.4.1 Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR).....	60
Section 2.5 Bioinformatics.....	61
2.5.1 ARH-77 and JJN-3 F $\kappa$ LC Dimer Phosphocholine Binding Models.....	61
Section 2.6 Suppliers.....	63
<b>CHAPTER 3: EXPRESSION OF KMA ON NORMAL B CELLS.....</b>	<b>64</b>
Section 3.1 Introduction.....	65

Section 3.2 Results .....	66
3.2.1 KMA is Expressed on in vitro Activated Plasmablasts and Plasma Cells .....	66
3.2.2 KMA is not Expressed on Peripheral Blood Plasma Cells .....	71
3.2.3 KMA is Expressed on a Subset of Tonsillar Plasma Cells .....	73
3.2.4 KMA+ Tonsillar Plasma Cells are Immature .....	77
Section 3.3 Discussion .....	78
<b>CHAPTER 4: MOLECULAR CHARACTERIZATION OF KMA.....</b>	<b>82</b>
Section 4.1 Introduction .....	83
Section 4.2 Results .....	85
4.2.1 KMA is Expressed on Lymphoblastoid Cell Lines .....	85
4.2.2 KMA Does not Associate with a Surface Receptor.....	86
4.2.3 KMA is Directly Associated with the Plasma Membrane .....	87
4.2.4 KMA is not Linked by a GPI Anchor.....	91
4.2.5 KMA is not Palmitoylated.....	92
4.2.6 KMA is not Linked to Cholesterol .....	93
4.2.7 KMA is not Linked via a Carbohydrate Anchor.....	94
Section 4.3 Discussion .....	96
<b>CHAPTER 5: MEMBRANE INTERACTIONS OF FκLC.....</b>	<b>98</b>
Section 5.1 Introduction .....	99
Section 5.2 Results .....	100
5.2.1 FκLC Binds to the Surface of Cells.....	100
5.2.2 Exogenous Membrane Bound FκLC is KMA .....	104
5.2.3 KMA Expression Arises Through the Normal Secretory Pathway .....	105
5.2.4 The Level of FκLC Secretion Does Not Correlate with KMA Expression .....	108
5.2.5 Recombinant κLC Expression Induces KMA .....	109
5.2.6 A FκLC Partially Oxidized Mutant Shows Greater Propensity to Bind Membranes and Form KMA.....	111
5.2.7 KMA is Fully Oxidized FκLC.....	113
5.2.8 Mild Heat Treatment of FκLC Induces Membrane Association .....	114
5.2.9 Mild Heat Treatment Aggregates FκLC.....	119
5.2.10 The V-domain is Required for KMA Expression .....	121
Section 5.3 Discussion .....	122
5.3.1 The Molecular Chaperone Hypothesis .....	126
5.3.2 The Native State Hypothesis .....	127
<b>CHAPTER 6: THE MOLECULAR CHAPERONE HYPOTHESIS.....</b>	<b>130</b>
Section 6.1 Introduction .....	131
Section 6.2 Results .....	133
6.2.1 Heat Shock Up-Regulates LC Chaperones and Lowers Expression of KMA .....	133
6.2.2 LC Chaperones are Down-Regulated in KMA Expressing Cell Lines.....	134
6.2.3 siRNA Knock-Down of GRP58, GRP78 and GRP94 Does Not Induce KMA Expression .....	136
Section 6.3 Discussion .....	139
<b>CHAPTER 7: THE NATIVE STATE HYPOTHESIS .....</b>	<b>141</b>
Section 7.1 Introduction .....	142
Section 7.2 Results .....	144
7.2.1 Cholesterol Depletion Disrupts KMA But Enhances Binding of FκLC to Cell Membranes .....	144
7.2.2 KMA is Co-Localized with the Lipid Raft Marker CD59 .....	146
7.2.3 KMA is TX100 Soluble at 4°C.....	148
7.2.4 FκLC Associates with Sphingomyelin and Saturated Phosphatidylcholine .....	150
7.2.5 Cholesterol Inhibits Binding of FκLC to Sphingomyelin.....	154

7.2.6 Cellular Cholesterol Levels are not a Factor in KMA Expression .....	156
7.2.7 KMA Expression is Dependent on Sphingomyelin.....	157
7.2.8 Structural Models of FκLC Display a Potential Phosphocholine Binding Pocket in the V-domain.....	162
<b>Section 7.3 Discussion .....</b>	<b>165</b>
7.3.1 Do FκLCs Associate with Lipid Rafts?.....	165
7.3.2 Interaction of Phosphocholine with the Conventional Antigen Binding Pocket of FκLCs.....	170
7.3.3 Aggregation as a Requirement for Membrane Association of FκLCs.....	172
7.3.4 Is KMA Expression Down-Regulated by N-SMases?.....	176
7.3.5 Toxicity of Protein Aggregates.....	176
7.3.6 Aggregated Membrane Proteins as a Target for Therapies .....	178
7.3.7 FλLCs Associate with Membranes.....	179
7.3.8 Possible Functions of FκLC Binding to Phosphocholine Lipids and Related Molecules .....	180
7.3.9 Concluding Remarks .....	183
<b>CHAPTER 8: SUMMARY AND CONCLUSIONS .....</b>	<b>185</b>
<b>BIBLIOGRAPHY .....</b>	<b>190</b>

## List of Figures and Tables

Figure 1.1: The polypeptide ribbon structure of an IgG Ab molecule. ....	6
Figure 1.2: $\kappa$ LC gene recombination and expression. ....	8
Figure 1.3: Polypeptide ribbon structure and schematic of a F $\kappa$ LC. ....	11
Figure 1.4: Phenotypes used to identify human B cells at different stages of differentiation. ....	22
Figure 1.5: LC deposition pathway. ....	26
Figure 1.6: Common lipids found in eukaryotic membranes. ....	33
Figure 1.7: Types of membrane proteins. ....	37
Figure 2.1: Sequence alignment of ARH-77 and JJN-3 $\kappa$ LC. ....	62
Figure 3.1: KMA expression on Protein A enriched SAC activated CD19+ peripheral B cells. ....	67
Figure 3.2: Phenotypic analysis of Protein A enriched SAC activated B cells. ....	68
Figure 3.3: KMA expression on IL-21, anti-CD40 and anti-IgM activated CD19+ peripheral B cells. ....	70
Figure 3.4: Phenotypic analysis of IL-21, anti-CD40 and anti-IgM activated B cells. ....	71
Figure 3.5: Analysis of KMA expression on peripheral blood plasma cells. ....	72
Figure 3.6: Analysis of KMA expression on TMNCs from Donor 1. ....	75
Figure 3.7: Analysis of KMA expression on TMNCs from Donor 2. ....	76
Figure 3.8: CD45 status on KMA+ tonsillar plasma cells. ....	77
Figure 3.9: Model of KMA expression during normal B cell differentiation. ....	79
Figure 4.1: KMA expression on lymphoblastoid cell lines. ....	85
Figure 4.2: Immunoprecipitation of KMA from JJN-3 and ARH-77_100 purified cellular membranes. ....	87
Figure 4.3: Sodium carbonate extraction of ARH-77_100 and JJN-3 membranes. ....	89
Figure 4.4: Effect of high salt, low pH washes on KMA expression. ....	90
Figure 4.5: TX114 phase extraction of JJN-3 purified membranes. ....	91
Figure 4.6: PLC treatment of ARH-77_100 cells. ....	92
Figure 4.7: Biotin palmitoyl exchange on membrane F $\kappa$ LC. ....	93
Figure 4.8: Effect of cholesterol esterase treatment on KMA expression. ....	94
Figure 4.9: O-Glycosidase treatment of ARH-77_100 cells. ....	95
Figure 5.1: Biotinylated F $\kappa$ LC bind to cell lines. ....	100
Figure 5.2: Biotinylated F $\kappa$ LC binds PBMCs. ....	102
Figure 5.3: Comparison of the binding of different biotinylated F $\kappa$ LC BJPs to MC-116 cells. ....	103
Figure 5.4: Comparison of binding biotinylated $\kappa$ Fab and F $\kappa$ LC to MC-116 cells. ....	104
Figure 5.5: Induction of KMA expression by exogenous F $\kappa$ LC. ....	105
Figure 5.6: Models of F $\kappa$ LC membrane association giving rise to surface expression of KMA. ....	106
Figure 5.7: Analysis of expression of KMA and CD59 after brefeldin A treatment of ARH-77_100 cells. ....	107
Figure 5.8: Comparison of F $\kappa$ LC secretion over time by $\kappa$ LC lymphoblastoid cell lines. ....	109
Figure 5.9: KMA expression on $\kappa$ LC transfected HEK-293 cells. ....	110
Figure 5.10: Comparison of secreted F $\kappa$ LC between wild type (WT) and C-terminal cysteine deleted (-cys) $\kappa$ LC HEK-293 transfectants. ....	112
Figure 5.11: Schematic diagrams of wild type (WT) and C-terminal cysteine deleted (-cys) F $\kappa$ LC synthesized by HEK-293 transfectants. ....	112
Figure 5.12: Analysis of oxidation state of membrane associated F $\kappa$ LC as KMA. ....	114
Figure 5.13: Mild heat treated biotinylated F $\kappa$ LC binding to MC116 cells. ....	115
Figure 5.14: Mild heat treated F $\kappa$ LC associates with LUVs. ....	117
Figure 5.15: KMA on the surface of LUVs. ....	118
Figure 5.16: DLS of VOR F $\kappa$ LC under different temperatures. ....	120
Figure 5.17: Comparison of KMA expression on HEK-293 cells transfected with full $\kappa$ LC or C-domain only $\kappa$ LC. ....	121

Figure 5.18: Membrane associated FκLC, as KMA, resides in a large molecular complex of approximately 450kDa. ....	123
Figure 5.19: Model of FκLC association with membranes as KMA.....	125
Figure 5.20: The molecular chaperone and native state hypotheses.....	128
Figure 6.1: FLC V-domain folding is dependent on molecular chaperones.....	132
Figure 6.2: Heat shock down-regulates KMA expression on JJN-3 cells.. ....	134
Figure 6.3: mRNA expression of κLC, GRP58, GRP78 and GRP94 in KMA positive and negative cell lines .....	136
Figure 6.4: siRNA knock-down of GRP58, GRP78 and GRP94 on NCI-H929. Analysis of KMA expression.....	138
Figure 7.1: Effect of cholesterol depletion on KMA expression.....	145
Figure 7.2: Effect of cholesterol depletion on FκLC binding to cellular membranes. ....	146
Figure 7.3: KMA co-localizes with CD59 on JJN-3 cells.....	148
Figure 7.4: Effect of TX100 at 4°C on KMA expression.....	150
Figure 7.5: Structure of phospholipids used in ELISA and LUV assays. ....	151
Figure 7.6: Binding of bVOR FκLC to various lipid monolayers.....	152
Figure 7.7: Assessment of VOR FκLC binding to different phosphocholine lipid based LUVs. ....	154
Figure 7.8: Binding of bVOR FκLC to sphingomyelin monolayers in the presence of cholesterol.....	156
Figure 7.9: Total cellular cholesterol content in KMA positive and negative cells... ..	157
Figure 7.10: Total cellular sphingomyelin content in KMA positive and KMA negative cells. ....	159
Figure 7.11: Measurement of sphingomyelin on the plasma membrane of KMA positive and KMA negative cells. ....	160
Figure 7.12: Effects of GW4869 N-Smase inhibitor on KMA expression of NCI-H929 and ARH-77_neg cells.....	161
Figure 7.13: The phosphocholine binding pocket of McPC603 κFab, ARH-77 and JJN-3 FκLC V-domain dimer models. ribbon and surface diagrams.....	164
Figure 7.14: Lipid raft and lipid raft-like membrane models.. ....	168
Figure 7.15: Model membranes containing saturated and unsaturated lipid species.....	170
Figure 8.1: Model for KMA expression by a FκLC secreting cell.....	189
Table 2.1: Cell lines used in this study.....	41
Table 2.2: Staining reagents used for flow cytometry experiments. ....	44
Table 2.3: siRNA sequences used in gene expression knockdown study. ....	49
Table 2.4: Abs and conjugates used for the detection of proteins by western blot.....	53
Table 2.5: Sequences of primers used in qPCR study.....	61

## Abbreviations

-	negative
+	positive
°C	degrees Celsius
$\alpha$	alpha
$\delta$	delta
$\epsilon$	epsilon
$\gamma$	gamma
$\kappa$	kappa
$\lambda$	lambda
$\mu$	mu
$\mu\text{g}$	microgram
$\mu\text{L}$	microlitre
$\text{\AA}$	angstrom
Ab	antibody
ADCC	antibody dependent cellular cytotoxicity
AIDS	acquired immune deficiency syndrome
AP	alkaline phosphatase
APC	allophycocyanin
APCs	antigen presenting cells
ATP	adenosine triphosphate
Auto-Ab	auto-antibody
Az	azide
BCR	B cell receptor
BiP	immunoglobulin heavy chain-binding protein
BJP	bence jones protein
b $\kappa$ Fab	biotinylated $\kappa$ Fab
BSA	bovine serum albumin
bVOR	biotinylated VOR

C3	complement component 3
CCDA	co-stimulatory cell dependent activation
CCIA	co-stimulatory cell independent activation
CD	cluster of differentiation
CDC	complement-dependent cytotoxicity
C-domain	constant domain
CDR	complementarity determining regions
D	diversity
Da	dalton
ddH <sub>2</sub> O	double distilled water
D <sub>H</sub>	hydrodynamic diameter
DLS	dynamic light scattering
DNA	deoxyribonucleic acid
DOPC	1,2-dioleoyl-sn-glycero-3- phosphatidylcholine
DTT	dithiothreitol
ECL	enzymatic chemiluminescence
ELISA	enzyme-linked immunoabsorbent assay
ER	endoplasmic reticulum
EWB	enzyme-linked immunoabsorbent assay wash buffer
EWB-T	enzyme-linked immunoabsorbent assay wash buffer with tween 20
Fab	fragment, antigen binding
Fc	crystallisable fragment
FITC	fluorescein
FLC	free immunoglobulin light chain
FκLC	free immunoglobulin kappa light chain
FλLC	free immunoglobulin lambda light chain
FSC	forward scatter
FSW	flow cytometry staining wash
g	gram or centrifugal force
GC	germinal centre
GFP	green fluorescent protein

gp41	glycoprotein 41
GPI	glycosylphosphatidylinositol
GRP	glucose-regulated protein
h	hours
HC	heavy chain
HCD	heavy chain disease
HRP	horse radish peroxidase
hsp	heat shock protein
Ig	immunoglobulin
IgA	immunoglobulin A
IgD	immunoglobulin D
IgE	immunoglobulin E
IgG	immunoglobulin G
IgM	immunoglobulin M
IL	interleukin
J	joining
k	kilo
kDa	kilodalton
KMA	kappa myeloma antigen
L	litre
LC	light chain
LCA	light chain amyloidosis
LCDD	light chain amorphous deposition disease
LMA	lambda myeloma antigen
LUV	large unilamellar vesicle
M	molar
mAb	monoclonal antibody
m $\beta$ CD	methyl $\beta$ cyclodextrin
mg	milligram
MGUS	monoclonal gammopathy of undetermined significance
MHC II	major histocompatibility complex class II

min	minutes
mL	millilitre
MM	multiple myeloma
mM	millimolar
M-protein	monoclonal protein
mRNA	messenger ribonucleic acid
MS	multiple sclerosis
MZ	marginal zone
nm	nanometer
N-Smase	neutral sphingomyelinase
OD	optical density
p	pico
PAGE	polyacrylamide gel electrophoresis
PAMPs	pathogen-associated molecular patterns
PBMCs	peripheral blood mononuclear cells
PBS	phosphate buffered saline
PDI	protein disulfide isomerase
PE	phycoerythrin
PerCP	peridinin-chlorophyll-protein complex
PLC	phospholipase C
POPC	1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine
POPE	1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylethanolamine
POPS	1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphatidylserine
qPCR	quantitative polymerase chain reaction
R10	RPMI 1640 media and 10% foetal bovine serum
RA	rheumatoid arthritis
RMSD	root mean square deviation
RNA	ribonucleic acid
RT	room temperature
RT-qPCR	reverse transcriptase quantitative polymerase chain reaction
RU	arbitrary response unit

s	second
SAC	<i>Staphylococcus aureus</i> cowan I strain
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
siRNA	small inhibitory ribonucleic acid
SLE	systemic lupus erythematosus
SP-A	surfactant protein-A
SPR	surface plasmon resonance
SSC	side scatter
TLR	toll-like receptor
TMNCs	tonsil derived mononuclear cells
TX100	triton X 100
TX114	triton X 114
V	variable
V-domain	variable domain
V(D)J	variable, (diversity), joining
VH	variable heavy chain
VL	variable light chain
WM	Waldenström's macroglobulinaemia
XBP-1	x-box binding protein 1

## Abstract

Kappa Myeloma Antigen (KMA) is a plasma membrane associated form of free immunoglobulin kappa light chain (FκLC) expressed on malignant B cells from patients with multiple myeloma (MM), Waldenström's macroglobulinaemia (WM) and non-Hodgkin's lymphoma (Walker et al. 1985). KMA is recognized by the murine monoclonal antibody (mAb) mKap, and its human-mouse chimeric equivalent, cKap, which is currently undergoing clinical trials as a therapy for kappa type MM (Boux et al. 1983; Raison et al. 2005).

Earlier expression studies on KMA suggested that the antigen is not expressed by normal B cells *in vivo*. However, *in vitro* activation of tonsillar B cells induced expression of KMA on a subset of cells. Like their KMA expressing malignant counterparts, these were presumed to be FκLC secreting plasma cells or plasmablasts but, due to the lack of B cell lineage specific markers at the time, these cells were not phenotyped (Walker et al. 1985). Furthermore, given the extremely low frequency of plasmablasts and plasma cells in normal tissues, it was not possible to exclude the presence of a 'normal' KMA positive cell population *in vivo*.

The first section of this thesis expands upon this earlier work. By utilizing *in vitro* activation protocols on peripheral blood CD19+ B cells, KMA expression was induced on a subset of cells. Phenotypic analysis revealed that the majority of KMA positive cells were CD27++ CD38+/- plasmablasts and CD38++ plasma cells. Analysis from normal human tissues found that a subset of plasma cells in the tonsils expressed the antigen. These cells co-expressed CD45, indicating that they are at an immature stage of plasma cell differentiation. In contrast, peripheral plasma cells, considered to be more fully mature cells in transit from secondary lymphoid organs to plasma cell niches in bone marrow or spleen, did not express KMA. This implies that KMA expression, *in vivo*, is limited to a small subset of immature plasma cells in secondary lymphoid organs such as the tonsils.

Despite cKap's current assessment in clinical trials for the treatment of MM, very little is known about its molecular target KMA. Previous studies have showed that KMA is comprised of FκLC (Goodnow and Raison 1985); however it was never determined as to how FκLC is associated with the plasma membrane. Since FκLC is a secreted molecule, it was initially presumed that it associated with a proteinaceous 'membrane receptor' (Goodnow and Raison 1985). However membrane extraction studies, as described in the second part of this thesis, reveal that FκLC directly associates with the plasma membrane through a combination of hydrophobic and electrostatic forces to form KMA. Further investigations confirmed that FκLCs can bind directly to cellular and artificial membranes. Moreover, this binding is likely dependent on self-association processes, which suggest that KMA consists of aggregated, membrane associated FκLCs.

Lipid binding studies revealed that FκLCs associate specifically with saturated phosphocholine species such as sphingomyelin in membranes, and KMA expression was positively correlated with sphingomyelin expression in FκLC secreting cell lines.

The final section of this thesis examines how FκLCs might interact with saturated phosphocholine lipids. Molecular modeling of dimeric FκLC suggests they are able to weakly associate with phosphocholine in the conventional antigen binding pocket formed by the κLC variable domain (V-domain). Since FκLC aggregation is a feature of KMA, then the avidity effects of multi-valent binding likely increases the strength of the proposed FκLC-phosphocholine interaction. This hypothesis explains the observation of both electrostatic and hydrophobic interactions by FκLC, as KMA, with the plasma membrane - the electrostatic component, governed by single FκLC molecules interacting with the charged phosphocholine headgroups, and the hydrophobic component, due to self-association of adjacent FκLC molecules.

Finally, a model of KMA expression by FκLC secreting cells is proposed. FκLC is synthesized in the endoplasmic reticulum (ER) then transported to the golgi-apparatus and encapsulated into vesicles destined for secretion. There FκLCs interact with saturated

phosphocholine lipids, such as sphingomyelin, and undergo aggregation resulting in stable association on the inner vesicular membrane. Fusion of the vesicle with the plasma membrane during exocytosis allows for membrane associated F $\kappa$ LC to become exposed on the extracellular face as KMA.